← Leaderboards
Arupratan Das
Johns Hopkins University
$933,178
Attributed
$933,178
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $249K · FY2017–22$250K$187.5K$125K$62.5K$0
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$933,178 · 2
By mechanism
R00$739,527 · 1
K99$193,651 · 1
Top collaborators
No co-investigators on record.
Most similar at Johns Hopkins University
Same institution · by research overlap
- Donald J Zack$29,428,568
- Andrew A Pieper$7,901,653
- Paul Fuchs$26,247,915
- Thomas W Kensler$20,869,769
- Harry Alan Quigley$23,425,626
Others in their field
Other Emerging Leaders on “Alleles”
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Evan Z Macosko · Broad Institute, Inc.$27,107,011
- Paul John Norman · University Of Colorado Denver$12,197,519
- Badri N Vardarajan · University Of Miami School Of Medicine$11,890,673
- Jacqueline K White · Jackson Laboratory$11,525,170
- Jessica Brooke Langbaum · Banner Health$11,370,996
Research focus
AllelesAmericanAmericasApoptosisAutophagocytosisAutophagosomeBaseBiologyBlindnessCell DeathCell Differentiation ProcessCell InjuryCell ModelCell PhysiologyCellsCell SurvivalCellular BiologyClustered Regularly Interspaced Short Palindromic RepeatsCollaborationsCrispr/Cas TechnologyDefectDegradation PathwayDependovirusDesign
Grant awards (5)
Use of Human Stem Cell-derived RGCs to Study the Mechanism of Optineurin-associated Glaucoma$248,999
R00 · FY2022 · EY · contact PI
Use of Human Stem Cell-derived RGCs to Study the Mechanism of Optineurin-associated Glaucoma$241,528
R00 · FY2021 · EY · contact PI
Use of Human Stem Cell-derived RGCs to Study the Mechanism of Optineurin-associated Glaucoma$249,000
R00 · FY2020 · EY · contact PI
Use of Human Stem Cell-derived RGCs to Study the Mechanism of Optineurin-associated Glaucoma$96,781
K99 · FY2018 · EY · contact PI
Use of Human Stem Cell-derived RGCs to Study the Mechanism of Optineurin-associated Glaucoma$96,870
K99 · FY2017 · EY · contact PI